MovDisordV3, PubMed, Curation, bibRecord, 003022

Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Identifieur interne : 003022 ( PubMed/Curation ); précédent : 003021; suivant : 003023

Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Auteurs : Daniel Weintraub [États-Unis] ; Knashawn H. Morales ; Paul J. Moberg ; Warren B. Bilker ; Catherine Balderston ; John E. Duda ; Ira R. Katz ; Matthew B. Stern

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.

RBID : pubmed:15954137

English descriptors

KwdEn :
- Antidepressive Agents (therapeutic use), Humans, Parkinson Disease (drug therapy).
MESH :
- chemical , therapeutic use : Antidepressive Agents.
- drug therapy : Parkinson Disease.
- Humans.

Abstract

The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta-analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta-analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD.

DOI: 10.1002/mds.20555
PubMed: 15954137

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003022

Links to Exploration step

pubmed:15954137

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antidepressant studies in Parkinson's disease: a review and meta-analysis.</title>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA. weintrau@mail.med.upenn.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Morales, Knashawn H" sort="Morales, Knashawn H" uniqKey="Morales K" first="Knashawn H" last="Morales">Knashawn H. Morales</name>
</author>
<author><name sortKey="Moberg, Paul J" sort="Moberg, Paul J" uniqKey="Moberg P" first="Paul J" last="Moberg">Paul J. Moberg</name>
</author>
<author><name sortKey="Bilker, Warren B" sort="Bilker, Warren B" uniqKey="Bilker W" first="Warren B" last="Bilker">Warren B. Bilker</name>
</author>
<author><name sortKey="Balderston, Catherine" sort="Balderston, Catherine" uniqKey="Balderston C" first="Catherine" last="Balderston">Catherine Balderston</name>
</author>
<author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E" last="Duda">John E. Duda</name>
</author>
<author><name sortKey="Katz, Ira R" sort="Katz, Ira R" uniqKey="Katz I" first="Ira R" last="Katz">Ira R. Katz</name>
</author>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B" last="Stern">Matthew B. Stern</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="doi">10.1002/mds.20555</idno>
<idno type="RBID">pubmed:15954137</idno>
<idno type="pmid">15954137</idno>
<idno type="wicri:Area/PubMed/Corpus">003022</idno>
<idno type="wicri:Area/PubMed/Curation">003022</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antidepressant studies in Parkinson's disease: a review and meta-analysis.</title>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA. weintrau@mail.med.upenn.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Morales, Knashawn H" sort="Morales, Knashawn H" uniqKey="Morales K" first="Knashawn H" last="Morales">Knashawn H. Morales</name>
</author>
<author><name sortKey="Moberg, Paul J" sort="Moberg, Paul J" uniqKey="Moberg P" first="Paul J" last="Moberg">Paul J. Moberg</name>
</author>
<author><name sortKey="Bilker, Warren B" sort="Bilker, Warren B" uniqKey="Bilker W" first="Warren B" last="Bilker">Warren B. Bilker</name>
</author>
<author><name sortKey="Balderston, Catherine" sort="Balderston, Catherine" uniqKey="Balderston C" first="Catherine" last="Balderston">Catherine Balderston</name>
</author>
<author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E" last="Duda">John E. Duda</name>
</author>
<author><name sortKey="Katz, Ira R" sort="Katz, Ira R" uniqKey="Katz I" first="Ira R" last="Katz">Ira R. Katz</name>
</author>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B" last="Stern">Matthew B. Stern</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressive Agents (therapeutic use)</term>
<term>Humans</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta-analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta-analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15954137</PMID>
<DateCreated><Year>2005</Year>
<Month>08</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>12</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>06</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20</Volume>
<Issue>9</Issue>
<PubDate><Year>2005</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Antidepressant studies in Parkinson's disease: a review and meta-analysis.</ArticleTitle>
<Pagination><MedlinePgn>1161-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta-analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta-analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD.</AbstractText>
<CopyrightInformation>(c) 2005 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weintraub</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA. weintrau@mail.med.upenn.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morales</LastName>
<ForeName>Knashawn H</ForeName>
<Initials>KH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moberg</LastName>
<ForeName>Paul J</ForeName>
<Initials>PJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bilker</LastName>
<ForeName>Warren B</ForeName>
<Initials>WB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Balderston</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Duda</LastName>
<ForeName>John E</ForeName>
<Initials>JE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Katz</LastName>
<ForeName>Ira R</ForeName>
<Initials>IR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stern</LastName>
<ForeName>Matthew B</ForeName>
<Initials>MB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>K23 MH067894</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K23 MH067894-04</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>MH067894</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2003 Jul;160(7):1277-85</RefSource>
<PMID Version="1">12832242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1996 Aug 28;276(8):637-9</RefSource>
<PMID Version="1">8773637</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2003 Dec;10(2):59-65</RefSource>
<PMID Version="1">14643994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 1969;45(1):109-13</RefSource>
<PMID Version="1">4896078</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 1972 Jan;26(1):57-63</RefSource>
<PMID Version="1">5009428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1977 Oct 15;2(8042):791-5</RefSource>
<PMID Version="1">71602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 1977;4Suppl 2:187S-190S</RefSource>
<PMID Version="1">334223</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Psychiatry. 1979 Apr;134:382-9</RefSource>
<PMID Version="1">444788</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 1980 Oct;62(4):210-9</RefSource>
<PMID Version="1">7010875</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Affect Disord. 1983 May;5(2):141-5</RefSource>
<PMID Version="1">6222093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1984 Aug;34(8):1092-4</RefSource>
<PMID Version="1">6431314</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1986 Jun;143(6):756-9</RefSource>
<PMID Version="1">2424323</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Sep;15(5):986-9</RefSource>
<PMID Version="1">11009210</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Oct 24;55(8):1216-8</RefSource>
<PMID Version="1">11071504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Nov;15(6):1225-9</RefSource>
<PMID Version="1">11104210</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):187-96</RefSource>
<PMID Version="1">11449025</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2001 Jul-Aug;24(4):221-7</RefSource>
<PMID Version="1">11479393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2002 Jan-Feb;25(1):21-4</RefSource>
<PMID Version="1">11852292</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gen Intern Med. 2002 Apr;17(4):293-301</RefSource>
<PMID Version="1">11972726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1997 May;54(5):625-30</RefSource>
<PMID Version="1">9152120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1997 Oct;49(4):1168-70</RefSource>
<PMID Version="1">9339713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1997 Sep;12(5):756-9</RefSource>
<PMID Version="1">9380061</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychosomatics. 1998 Sep-Oct;39(5):416-21</RefSource>
<PMID Version="1">9775698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1999;80:505-8</RefSource>
<PMID Version="1">10410764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 1999 Sep;14(9):711-8</RefSource>
<PMID Version="1">10479741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 1965 Jan;12:63-70</RefSource>
<PMID Version="1">14221692</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br Med J. 1965 Jul 3;2(5452):33-4</RefSource>
<PMID Version="1">14305352</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</RefSource>
<PMID Version="1">14399272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Postgrad Med. 2001 Oct;Spec No Pharmacotherapy:1-86</RefSource>
<PMID Version="1">17205639</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Geriatr Psychiatry. 2002 May-Jun;10(3):256-64</RefSource>
<PMID Version="1">11994212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2002 Apr;63(4):300-4</RefSource>
<PMID Version="1">12000202</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2002 Jun;25(6):302-6</RefSource>
<PMID Version="1">12086748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2002 Aug;54(2):168-70</RefSource>
<PMID Version="1">12207636</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002;17 Suppl 4:S112-9</RefSource>
<PMID Version="1">12211151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2003 Winter;15(1):74-7</RefSource>
<PMID Version="1">12556575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 2003 Jun;18(6):552-4</RefSource>
<PMID Version="1">12789682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 1987;25:137-47</RefSource>
<PMID Version="1">3123600</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 1987;25:97-104</RefSource>
<PMID Version="1">3123607</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1988 Nov;38(11):1720-2</RefSource>
<PMID Version="1">3054626</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Nerv Ment Dis. 1990 Jan;178(1):27-31</RefSource>
<PMID Version="1">2295885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 1991 Nov;84(5):407-10</RefSource>
<PMID Version="1">1776388</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1992 Mar;42(3 Pt 1):541-4</RefSource>
<PMID Version="1">1549214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand Suppl. 1991;136:73-8</RefSource>
<PMID Version="1">1801541</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int Psychogeriatr. 1995 Spring;7(1):89-104</RefSource>
<PMID Version="1">7579025</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 1995 Summer;7(3):281-6</RefSource>
<PMID Version="1">7580184</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1996 Feb;53(2):175-9</RefSource>
<PMID Version="1">8639068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Geriatr Psychiatry Neurol. 2003 Sep;16(3):178-83</RefSource>
<PMID Version="1">12967062</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>67</NumberOfReferences>
<OtherID Source="NLM">NIHMS29020</OtherID>
<OtherID Source="NLM">PMC1989731</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20555</ArticleId>
<ArticleId IdType="pubmed">15954137</ArticleId>
<ArticleId IdType="pmc">PMC1989731</ArticleId>
<ArticleId IdType="mid">NIHMS29020</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003022 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003022 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15954137
   |texte=   Antidepressant studies in Parkinson's disease: a review and meta-analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15954137" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki